Acadia looks to 'blow up the paradigm' with Parkinson's psychosis drug Nuplazid

When doctors first give patients their Parkinson’s diagnoses, their main focus is motor control. And Acadia Pharmaceuticals, maker of Parkinson’s psychosis drug Nuplazid, gets that. But that very fact has given Acadia a big job to do with Nuplazid.